Quick Answer
Viridian Therapeutics, Inc.DE reported Net Income of -$342.60 million for fiscal year 2025.
Viridian Therapeutics, Inc.DE Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$342.60M | -26.9% |
| 2024 | -$269.95M | -13.6% |
| 2023 | -$237.73M | -83.0% |
| 2022 | -$129.87M | -63.5% |
| 2021 | -$79.41M | +28.3% |
| 2020 | -$110.72M | -164.4% |
| 2019 | -$41.87M | -28.0% |
| 2018 | -$32.70M | -23.4% |
| 2017 | -$26.51M | -53.5% |
| 2016 | -$17.27M | -52.5% |
| 2015 | -$11.33M | -43.6% |
| 2014 | -$7.89M | -265.3% |
| 2013 | -$2.16M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$34.60M | +54.9% | +65.7% |
| June 30, 2025 | -$100.73M | -55.0% | -15.9% |
| March 31, 2025 | -$86.91M | -79.0% | -13.3% |
| September 30, 2024 | -$76.69M | -60.9% | -18.0% |
| June 30, 2024 | -$64.99M | -18.0% | -33.9% |
| March 31, 2024 | -$48.54M | +28.8% | -1.9% |
| September 30, 2023 | -$47.66M | -64.9% | +13.4% |
| June 30, 2023 | -$55.06M | -86.7% | +19.2% |
- Viridian Therapeutics, Inc.DE showed a decrease of -26.9% in Net Income compared to the prior fiscal year.
- Over the 2013–2025 period, Viridian Therapeutics, Inc.DE’s net income has declined by 15761.2% (from -$2.16 million to -$342.60 million).
- The most recent figure is from Viridian Therapeutics, Inc.DE’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: